Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2024

Open Access 01-12-2024 | Acute Coronary Syndrome | Research

Superoxide dismutases: marker in predicting reduced left ventricular ejection fraction in patients with type 2 diabetes and acute coronary syndrome

Authors: Xiu-Yun Jiang, Qing Chen, Xiao-Yu Chen, Qiu-Ying Sun, Fei Jing, Hai-Qing Zhang, Jin Xu, Xiao-Hong Li, Qing-Bo Guan

Published in: BMC Cardiovascular Disorders | Issue 1/2024

Login to get access

Abstract

Aim

To examine the prognostic value of superoxide dismutase (SOD) activity for monitoring reduced left ventricular ejection fraction(LVEF)in the patients with type 2 diabetes and acute coronary syndrome (ACS).

Methods

The population of this cross-sectional study included 2377 inpatients with type 2 diabetes who had an ACS admitted to the Shandong Provincial Hospital Affiliated to Shandong First Medical University from January 2016 to January 2021.

Results

Diabetic patients with ACS were divided into 2 subgroups based on LVEF. The mean SOD activity was significantly lower in patients with an LVEF ≤ 45% than in those with an LVEF > 45% (149.1 (146.4, 151.9) versus 161.9 (160.8, 163.0)). Using ROC statistic, a cut-off value of 148.8 U/ml indicated an LVEF ≤ 45% with a sensitivity of 51.6% and a specificity of 73.7%. SODs activity were found to be correlated with the levels of NT-proBNP, hs-cTnT, the inflammatory marker CRP and fibrinogen. Despite taking the lowest quartile as a reference (OR 0.368, 95% CI 0.493–0.825, P = 0.001) or examining 1 normalized unit increase (OR 0.651, 95% CI 0.482–0.880, P = 0.005), SOD activity was found to be a stronger predictor of reduced LVEF than CRP and fibrinogen, independent of confounding factors.

Conclusions

Our cross-sectional study suggests that SOD activity might be a valuable and easily accessible tool for assessing and monitoring reduced LVEF in the diabetic patients with ACS.
Literature
2.
go back to reference Rawshani A, Franzen S, Sattar N, Eliasson B, Svensson AM, Zethelius B, et al. Risk factors, mortality, and Cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–44. Epub 2018/08/16.CrossRefPubMed Rawshani A, Franzen S, Sattar N, Eliasson B, Svensson AM, Zethelius B, et al. Risk factors, mortality, and Cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–44. Epub 2018/08/16.CrossRefPubMed
3.
go back to reference Karakayali M, Omar T, Artac I, Ilis D, Arslan A, Altunova M, et al. The prognostic value of HALP score in predicting in-hospital mortality in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis. 2023;34(7):483–8. Epub 2023/10/06.CrossRefPubMed Karakayali M, Omar T, Artac I, Ilis D, Arslan A, Altunova M, et al. The prognostic value of HALP score in predicting in-hospital mortality in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis. 2023;34(7):483–8. Epub 2023/10/06.CrossRefPubMed
4.
go back to reference Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102(17):2031–7. Epub 2000/10/25.CrossRefPubMed Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102(17):2031–7. Epub 2000/10/25.CrossRefPubMed
5.
go back to reference Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091. Epub 2006/10/13.CrossRefPubMedPubMedCentral Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091. Epub 2006/10/13.CrossRefPubMedPubMedCentral
6.
go back to reference Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112(24):3738–44. Epub 2005/12/07.CrossRefPubMed Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112(24):3738–44. Epub 2005/12/07.CrossRefPubMed
7.
go back to reference Chew DS, Heikki H, Schmidt G, Kavanagh KM, Dommasch M, Bloch Thomsen PE, et al. Change in Left Ventricular Ejection Fraction following first myocardial infarction and outcome. JACC Clin Electrophysiol. 2018;4(5):672–82. Epub 2018/05/26.CrossRefPubMed Chew DS, Heikki H, Schmidt G, Kavanagh KM, Dommasch M, Bloch Thomsen PE, et al. Change in Left Ventricular Ejection Fraction following first myocardial infarction and outcome. JACC Clin Electrophysiol. 2018;4(5):672–82. Epub 2018/05/26.CrossRefPubMed
8.
go back to reference Yildiz I, Rencuzogullari I, Karabag Y, Karakayali M, Artac I, Gurevin MS. Predictors of left ventricular ejection function decline in young patients with ST-segment elevation myocardial infarction. Rev Assoc Med Bras (1992). 2022;68(6):802–7. Epub 2022/06/30.CrossRefPubMed Yildiz I, Rencuzogullari I, Karabag Y, Karakayali M, Artac I, Gurevin MS. Predictors of left ventricular ejection function decline in young patients with ST-segment elevation myocardial infarction. Rev Assoc Med Bras (1992). 2022;68(6):802–7. Epub 2022/06/30.CrossRefPubMed
9.
go back to reference Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation. 2002;106(24):3073–8. Epub 2002/12/11.CrossRefPubMed Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation. 2002;106(24):3073–8. Epub 2002/12/11.CrossRefPubMed
10.
go back to reference Barac A, Wang H, Shara NM, de Simone G, Carter EA, Umans JG, et al. Markers of inflammation, metabolic risk factors, and incident heart failure in American indians: the strong heart study. J Clin Hypertens (Greenwich). 2012;14(1):13–9. Epub 2012/01/13.CrossRefPubMed Barac A, Wang H, Shara NM, de Simone G, Carter EA, Umans JG, et al. Markers of inflammation, metabolic risk factors, and incident heart failure in American indians: the strong heart study. J Clin Hypertens (Greenwich). 2012;14(1):13–9. Epub 2012/01/13.CrossRefPubMed
11.
go back to reference Wang XY, Zhang F, Zhang C, Zheng LR, Yang J. The biomarkers for Acute myocardial infarction and heart failure. Biomed Res Int. 2020;2020:2018035. Epub 2020/02/06.PubMedPubMedCentral Wang XY, Zhang F, Zhang C, Zheng LR, Yang J. The biomarkers for Acute myocardial infarction and heart failure. Biomed Res Int. 2020;2020:2018035. Epub 2020/02/06.PubMedPubMedCentral
12.
go back to reference Li X, Lin Y, Wang S, Zhou S, Ju J, Wang X, et al. Extracellular superoxide dismutase is Associated with Left Ventricular geometry and heart failure in patients with Cardiovascular Disease. J Am Heart Association. 2020;9(15):e016862. Epub 2020/08/05.CrossRef Li X, Lin Y, Wang S, Zhou S, Ju J, Wang X, et al. Extracellular superoxide dismutase is Associated with Left Ventricular geometry and heart failure in patients with Cardiovascular Disease. J Am Heart Association. 2020;9(15):e016862. Epub 2020/08/05.CrossRef
13.
go back to reference Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, et al. Rationale, design, and baseline characteristics in evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J. 2015;169(5):631–8. e7. Epub 2015/05/13.CrossRefPubMed Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, et al. Rationale, design, and baseline characteristics in evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J. 2015;169(5):631–8. e7. Epub 2015/05/13.CrossRefPubMed
14.
go back to reference Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on standards, Subcommittee on quantitation of two-Dimensional echocardiograms. J Am Soc Echocardiography: Official Publication Am Soc Echocardiography. 1989;2(5):358–67. Epub 1989/09/01.CrossRef Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on standards, Subcommittee on quantitation of two-Dimensional echocardiograms. J Am Soc Echocardiography: Official Publication Am Soc Echocardiography. 1989;2(5):358–67. Epub 1989/09/01.CrossRef
15.
go back to reference Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. Epub 2016/05/22.CrossRefPubMed Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. Epub 2016/05/22.CrossRefPubMed
16.
go back to reference Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the management of Acute Coronary syndromes in patients presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315. Epub 2015/09/01.CrossRefPubMed Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the management of Acute Coronary syndromes in patients presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315. Epub 2015/09/01.CrossRefPubMed
17.
go back to reference Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol. 1996;148(1):291–300. Epub 1996/01/01.PubMedPubMedCentral Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol. 1996;148(1):291–300. Epub 1996/01/01.PubMedPubMedCentral
18.
go back to reference Khaper N, Kaur K, Li T, Farahmand F, Singal PK. Antioxidant enzyme gene expression in congestive heart failure following myocardial infarction. Mol Cell Biochem. 2003;251(1–2):9–15. Epub 2003/10/25.CrossRefPubMed Khaper N, Kaur K, Li T, Farahmand F, Singal PK. Antioxidant enzyme gene expression in congestive heart failure following myocardial infarction. Mol Cell Biochem. 2003;251(1–2):9–15. Epub 2003/10/25.CrossRefPubMed
19.
go back to reference van Deel ED, Lu Z, Xu X, Zhu G, Hu X, Oury TD, et al. Extracellular superoxide dismutase protects the heart against oxidative stress and hypertrophy after myocardial infarction. Free Radic Biol Med. 2008;44(7):1305–13. Epub 2008/01/22.CrossRefPubMed van Deel ED, Lu Z, Xu X, Zhu G, Hu X, Oury TD, et al. Extracellular superoxide dismutase protects the heart against oxidative stress and hypertrophy after myocardial infarction. Free Radic Biol Med. 2008;44(7):1305–13. Epub 2008/01/22.CrossRefPubMed
20.
go back to reference Wang P, Chen H, Qin H, Sankarapandi S, Becher MW, Wong PC, et al. Overexpression of human copper, zinc-superoxide dismutase (SOD1) prevents postischemic injury. Proc Natl Acad Sci USA. 1998;95(8):4556–60. Epub 1998/05/16.CrossRefPubMedPubMedCentral Wang P, Chen H, Qin H, Sankarapandi S, Becher MW, Wong PC, et al. Overexpression of human copper, zinc-superoxide dismutase (SOD1) prevents postischemic injury. Proc Natl Acad Sci USA. 1998;95(8):4556–60. Epub 1998/05/16.CrossRefPubMedPubMedCentral
21.
go back to reference Iida S, Chu Y, Weiss RM, Kang YM, Faraci FM, Heistad DD. Vascular effects of a common gene variant of extracellular superoxide dismutase in heart failure. Am J Physiol Heart Circ Physiol. 2006;291(2):H914–20. Epub 2006/07/15.CrossRefPubMed Iida S, Chu Y, Weiss RM, Kang YM, Faraci FM, Heistad DD. Vascular effects of a common gene variant of extracellular superoxide dismutase in heart failure. Am J Physiol Heart Circ Physiol. 2006;291(2):H914–20. Epub 2006/07/15.CrossRefPubMed
22.
go back to reference Juul K, Tybjaerg-Hansen A, Marklund S, Heegaard NH, Steffensen R, Sillesen H, et al. Genetically reduced antioxidative protection and increased ischemic heart disease risk: the Copenhagen City Heart Study. Circulation. 2004;109(1):59–65. Epub 2003/12/10.CrossRefPubMed Juul K, Tybjaerg-Hansen A, Marklund S, Heegaard NH, Steffensen R, Sillesen H, et al. Genetically reduced antioxidative protection and increased ischemic heart disease risk: the Copenhagen City Heart Study. Circulation. 2004;109(1):59–65. Epub 2003/12/10.CrossRefPubMed
23.
go back to reference Chu Y, Alwahdani A, Iida S, Lund DD, Faraci FM, Heistad DD. Vascular effects of the human extracellular superoxide dismutase R213G variant. Circulation. 2005;112(7):1047–53. Epub 2005/08/10.CrossRefPubMed Chu Y, Alwahdani A, Iida S, Lund DD, Faraci FM, Heistad DD. Vascular effects of the human extracellular superoxide dismutase R213G variant. Circulation. 2005;112(7):1047–53. Epub 2005/08/10.CrossRefPubMed
25.
go back to reference Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999;99(7):855–60. Epub 1999/02/23.CrossRefPubMed Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999;99(7):855–60. Epub 1999/02/23.CrossRefPubMed
26.
go back to reference Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557–65. Epub 2002/11/15.CrossRefPubMed Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557–65. Epub 2002/11/15.CrossRefPubMed
27.
go back to reference Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–8. Epub 2005/01/07.CrossRefPubMed Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–8. Epub 2005/01/07.CrossRefPubMed
28.
go back to reference de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J. 1982;47(3):239–43. Epub 1982/03/01.CrossRefPubMedPubMedCentral de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J. 1982;47(3):239–43. Epub 1982/03/01.CrossRefPubMedPubMedCentral
29.
go back to reference Palmieri V, Celentano A, Roman MJ, de Simone G, Best L, Lewis MR, et al. Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the strong heart study. Am Heart J. 2003;145(3):467–74. Epub 2003/03/28.CrossRefPubMed Palmieri V, Celentano A, Roman MJ, de Simone G, Best L, Lewis MR, et al. Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the strong heart study. Am Heart J. 2003;145(3):467–74. Epub 2003/03/28.CrossRefPubMed
30.
go back to reference Bahrami H, Bluemke DA, Kronmal R, Bertoni AG, Lloyd-Jones DM, Shahar E, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (multi-ethnic study of atherosclerosis) study. J Am Coll Cardiol. 2008;51(18):1775–83. Epub 2008/05/03.CrossRefPubMed Bahrami H, Bluemke DA, Kronmal R, Bertoni AG, Lloyd-Jones DM, Shahar E, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (multi-ethnic study of atherosclerosis) study. J Am Coll Cardiol. 2008;51(18):1775–83. Epub 2008/05/03.CrossRefPubMed
31.
go back to reference Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005;112(10):1428–34. Epub 2005/09/01.CrossRefPubMed Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005;112(10):1428–34. Epub 2005/09/01.CrossRefPubMed
32.
go back to reference Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, Tracy RP. C-reactive protein and myocardial infarction. J Clin Epidemiol. 2002;55(5):445–51. Epub 2002/05/15.CrossRefPubMed Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, Tracy RP. C-reactive protein and myocardial infarction. J Clin Epidemiol. 2002;55(5):445–51. Epub 2002/05/15.CrossRefPubMed
33.
go back to reference Best LG, Zhang Y, Lee ET, Yeh JL, Cowan L, Palmieri V, et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the strong heart study. Circulation. 2005;112(9):1289–95. Epub 2005/08/24.CrossRefPubMed Best LG, Zhang Y, Lee ET, Yeh JL, Cowan L, Palmieri V, et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the strong heart study. Circulation. 2005;112(9):1289–95. Epub 2005/08/24.CrossRefPubMed
34.
go back to reference Biasucci LM, Liuzzo G, Della Bona R, Leo M, Biasillo G, Angiolillo DJ, et al. Different apparent prognostic value of hsCRP in type 2 diabetic and nondiabetic patients with acute coronary syndromes. Clin Chem. 2009;55(2):365–8. Epub 2009/01/31.CrossRefPubMed Biasucci LM, Liuzzo G, Della Bona R, Leo M, Biasillo G, Angiolillo DJ, et al. Different apparent prognostic value of hsCRP in type 2 diabetic and nondiabetic patients with acute coronary syndromes. Clin Chem. 2009;55(2):365–8. Epub 2009/01/31.CrossRefPubMed
35.
go back to reference Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132–40. Epub 2009/12/25.CrossRefPubMed Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132–40. Epub 2009/12/25.CrossRefPubMed
36.
go back to reference Kengne AP, Batty GD, Hamer M, Stamatakis E, Czernichow S. Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 participants from four U.K. prospective cohort studies. Diabetes Care. 2012;35(2):396–403. Epub 2012/01/03.CrossRefPubMedPubMedCentral Kengne AP, Batty GD, Hamer M, Stamatakis E, Czernichow S. Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 participants from four U.K. prospective cohort studies. Diabetes Care. 2012;35(2):396–403. Epub 2012/01/03.CrossRefPubMedPubMedCentral
37.
go back to reference Lofblad L, Hov GG, Asberg A, Videm V. Inflammatory markers and risk of cardiovascular mortality in relation to diabetes status in the HUNT study. Sci Rep. 2021;11(1):15644. Epub 2021/08/04.CrossRefPubMedPubMedCentral Lofblad L, Hov GG, Asberg A, Videm V. Inflammatory markers and risk of cardiovascular mortality in relation to diabetes status in the HUNT study. Sci Rep. 2021;11(1):15644. Epub 2021/08/04.CrossRefPubMedPubMedCentral
38.
go back to reference Sinning JM, Bickel C, Messow CM, Schnabel R, Lubos E, Rupprecht HJ, et al. Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study. Eur Heart J. 2006;27(24):2962–8. Epub 2006/11/30.CrossRefPubMed Sinning JM, Bickel C, Messow CM, Schnabel R, Lubos E, Rupprecht HJ, et al. Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study. Eur Heart J. 2006;27(24):2962–8. Epub 2006/11/30.CrossRefPubMed
39.
go back to reference Hornig B, Arakawa N, Kohler C, Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation. 1998;97(4):363–8. Epub 1998/02/19.CrossRefPubMed Hornig B, Arakawa N, Kohler C, Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation. 1998;97(4):363–8. Epub 1998/02/19.CrossRefPubMed
40.
go back to reference Alcaino H, Greig D, Chiong M, Verdejo H, Miranda R, Concepcion R, et al. Serum uric acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure. Eur J Heart Fail. 2008;10(7):646–51. Epub 2008/06/19.CrossRefPubMed Alcaino H, Greig D, Chiong M, Verdejo H, Miranda R, Concepcion R, et al. Serum uric acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure. Eur J Heart Fail. 2008;10(7):646–51. Epub 2008/06/19.CrossRefPubMed
41.
go back to reference Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175(6):996–1004. Epub 2015/04/22.CrossRefPubMedPubMedCentral Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175(6):996–1004. Epub 2015/04/22.CrossRefPubMedPubMedCentral
42.
go back to reference Ho JE, Enserro D, Brouwers FP, Kizer JR, Shah SJ, Psaty BM et al. Predicting Heart failure with preserved and reduced ejection fraction: the international collaboration on heart failure subtypes. Circulation Heart Fail. 2016;9(6). Epub 2016/06/09. Ho JE, Enserro D, Brouwers FP, Kizer JR, Shah SJ, Psaty BM et al. Predicting Heart failure with preserved and reduced ejection fraction: the international collaboration on heart failure subtypes. Circulation Heart Fail. 2016;9(6). Epub 2016/06/09.
43.
go back to reference Lam CSP, Arnott C, Beale AL, Chandramouli C, Hilfiker-Kleiner D, Kaye DM et al. Sex differences in heart failure. European heart journal. 2019;40(47):3859-68c. Epub 2019/12/05. Lam CSP, Arnott C, Beale AL, Chandramouli C, Hilfiker-Kleiner D, Kaye DM et al. Sex differences in heart failure. European heart journal. 2019;40(47):3859-68c. Epub 2019/12/05.
Metadata
Title
Superoxide dismutases: marker in predicting reduced left ventricular ejection fraction in patients with type 2 diabetes and acute coronary syndrome
Authors
Xiu-Yun Jiang
Qing Chen
Xiao-Yu Chen
Qiu-Ying Sun
Fei Jing
Hai-Qing Zhang
Jin Xu
Xiao-Hong Li
Qing-Bo Guan
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2024
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-024-03867-2

Other articles of this Issue 1/2024

BMC Cardiovascular Disorders 1/2024 Go to the issue